KineMed and Amgen to Develop Kinetic Biomarkers of Brain Proteinopathies
News Oct 15, 2013
KineMed, Inc. announce an agreement with Amgen to apply KineMed’s mass spectrometric Dynamic Proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases.
“Normal brain aging and neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases, are characterized by the accumulation of misfolded proteins in the brain. Diagnostic tests have not previously been available that reflect the underlying dynamics of the proteins believed to play a causal role in neurodegeneration. This has been a major obstacle in developing drugs that slow the accumulation of these misfolded proteins,” said Dr. Fanara, Vice President of Neuroscience at KineMed and Principal Investigator on this study.
Neurodegenerative disease is a significant health burden worldwide with few effective treatment options available to patients; according to the Harvard NeuroDiscovery Center, without the development of new treatments, in 30 years’ time more than 12 million Americans may be suffering from some form of neurodegenerative disease. The growing number of patients underscores the urgent need to build new tools to guide and accelerate the development of effective treatments for neurodegenerative disease.
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.